CAMBRIDGE, MA / ACCESS Newswire / May 27, 2025 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the ...

Panel members had questions about whether a new FDA proposal to require randomized trials for vaccines in healthy adults ...

This update covers the latest health sector developments, including Moderna's COVID-19 vaccine review, GSK's asthma drug FDA ...

This summary provides insights into key developments in the health sector, covering successful Hong Kong listings, animal ...

CAMBRIDGE, MA / ACCESS Newswire / May 23, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that it has submitted an ...

The revised version of the vaccine, marketed as Spikevax, follows FDA guidance recommending that this year’s shots target ...

About a year after investing in Vigil Neuroscience Inc., Sanofi is now acquiring the Watertown biotech and its treatment in ...

Infectious disease experts say mRNA vaccines have been studied for decades, they are safe and effective, and were instrumental in saving lives during the COVID pandemic.

The FDA will limit the vaccine’s availability later this year to older adults and those who may be at risk of severe illness.

Analysts have set 12-month price targets for Moderna, revealing an average target of $37.62, a high estimate of $70.00, and a ...

FDA now requires Pfizer and Moderna COVID-19 vaccines to carry expanded warning labels about risks of myocarditis and pericarditis ...